Altimmune (ALT) Proxy Filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on April 16, 2026, with voting on key proposals including director elections, auditor ratification, executive compensation, amendments to the certificate of incorporation and employee stock purchase plan, and potential adjournment authorization.

• Stockholders of record as of March 13, 2026, are eligible to vote, with 130,105,177 shares outstanding.

• Voting can be conducted online, by phone, mail, or during the virtual meeting using a control number.

Voting matters and shareholder proposals

• Proposals include electing nine directors for one-year terms, ratifying Ernst & Young LLP as auditor, advisory vote on executive compensation, increasing authorized common stock, amending the 2019 Employee Stock Purchase Plan, and authorizing adjournment if needed.

• No stockholder proposals are included for this meeting.

Board of directors and corporate governance

• The board consists of nine members, with Jerome Durso as Chairman, President, and CEO; all other directors are independent.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.

• Board skills matrix highlights expertise in public company governance, finance, clinical development, commercial operations, and risk management.

• Regular executive sessions are held without management, and a Lead Independent Director was appointed in 2026.